|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fentiman IS, Fourquet A and Hortobagyi GN:
Male breast cancer. Lancet. 367:595–604. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kroemer G, Senovilla L, Galluzzi L, André
F and Zitvogel L: Natural and therapy-induced immunosurveillance in
breast cancer. Nat Med. 21:1128–1138. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spanheimer PM, Carr JC, Thomas A, Sugg SL,
Scott-Conner CE, Liao J and Weigel RJ: The response to neoadjuvant
chemotherapy predicts clinical outcome and increases breast
conservation in advanced breast cancer. Am J Surg. 206:2–7. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang X, Kanda T, Wu S, Nakamura M,
Miyamura T, Nakamoto S, Banerjee A and Yokosuka O: Regulation of
microRNA by hepatitis B virus infection and their possible
association with control of innate immunity. World J Gastroenterol.
20:7197–7206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Day E and Lal A: MicroRNAs and their
target gene networks in breast cancer. Breast Cancer Res.
12:2012010. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sakurai M, Masuda M, Miki Y, Hirakawa H,
Suzuki T and Sasano H: Correlation of miRNA expression profiling in
surgical pathology materials, with Ki-67, HER2, ER and PR in breast
cancer patients. Int J Biol Markers. 30:e190–e199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Antolín S, Calvo L, Blanco-Calvo M,
Santiago MP, Lorenzo-Patiño MJ, Haz-Conde M, Santamarina I,
Figueroa A, Antón-Aparicio LM and Valladares-Ayerbes M: Circulating
miR-200c and miR-141 and outcomes in patients with breast cancer.
BMC Cancer. 15:2972015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y,
Kong R, Luo Y, Shi Y, Wang K, et al: miR-206 is down-regulated in
breast cancer and inhibits cell proliferation through the
up-regulation of cyclinD2. Biochem Biophys Res Commun. 433:207–212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao Y, Zeng F, Wu JY, Li HY, Fan JJ, Mai
L, Zhang J, Ma DM, Li Y and Song FZ: MiR-335 inhibits migration of
breast cancer cells through targeting oncoprotein c-Met. Tumour
Biol. 36:2875–2883. 2015. View Article : Google Scholar
|
|
15
|
Song L, Liu D, Wang B, He J, Zhang S, Dai
Z, Ma X and Wang X: miR-494 suppresses the progression of breast
cancer in vitro by targeting CXCR4 through the Wnt/β-catenin
signaling pathway. Oncol Rep. 34:525–531. 2015.PubMed/NCBI
|
|
16
|
Xie X, Hu Y, Xu L, Fu Y, Tu J, Zhao H,
Zhang S, Hong R and Gu X: The role of
miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance
and therapy in human breast cancer. Tumour Biol. 36:7185–7194.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Mao Q, Liu Y, Hao X, Zhang S and
Zhang J: Analysis of miR-205 and miR-155 expression in the blood of
breast cancer patients. Chin J Cancer Res. 25:46–54.
2013.PubMed/NCBI
|
|
18
|
Müller V, Gade S, Steinbach B, Loibl S,
von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching
PA, et al: Changes in serum levels of miR-21, miR-210, and miR-373
in HER2-positive breast cancer patients undergoing neoadjuvant
therapy: A translational research project within the Geparquinto
trial. Breast Cancer Res Treat. 147:61–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang X, Wang X, Shen H, Deng R and Xue K:
Combination of mir-21 with circulating tumor cells markers improve
diagnostic specificity of metastatic breast cancer. Cell Biochem
Biophys. 73:87–91. 2015. View Article : Google Scholar
|
|
20
|
Han X, Yan S, Weijie Z, Feng W, Liuxing W,
Mengquan L and Qingxia F: Critical role of miR-10b in transforming
growth factor-β1-induced epithelial-mesenchymal transition in
breast cancer. Cancer Gene Ther. 21:60–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Derfoul A, Juan AH, Difilippantonio MJ,
Palanisamy N, Ried T and Sartorelli V: Decreased microRNA-214
levels in breast cancer cells coincides with increased cell
proliferation, invasion and accumulation of the Polycomb Ezh2
methyltransferase. Carcinogenesis. 32:1607–1614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han G, Fan M and Zhang X: microRNA-218
inhibits prostate cancer cell growth and promotes apoptosis by
repressing TPD52 expression. Biochem Biophys Res Commun.
456:804–809. 2015. View Article : Google Scholar
|
|
23
|
Dong Y, Zou J, Su S, Huang H, Deng Y, Wang
B and Li W: MicroRNA-218 and microRNA-520a inhibit cell
proliferation by downregulating E2F2 in hepatocellular carcinoma.
Mol Med Rep. 12:1016–1022. 2015.PubMed/NCBI
|
|
24
|
Zhang Y, Han D, Wei W, Cao W, Zhang R,
Dong Q, Zhang J, Wang Y and Liu N: MiR-218 inhibited growth and
metabolism of human glioblastoma cells by directly targeting E2F2.
Cell Mol Neurobiol. 35:1165–1173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang Z, Chen S, Luan X, Li Y, Liu M, Li X,
Liu T and Tang H: MicroRNA-214 is aberrantly expressed in cervical
cancers and inhibits the growth of HeLa cells. IUBMB Life.
61:1075–1082. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Peng RQ, Wan HY, Li HF, Liu M, Li X and
Tang H: MicroRNA-214 suppresses growth and invasiveness of cervical
cancer cells by targeting
UDP-N-acetyl-α-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 7. J Biol Chem. 287:14301–14309.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiang R, Wang F, Shi LY, Liu M, Chen S,
Wan HY, Li YX, Li X, Gao SY and Sun BC: Plexin-B1 is a target of
miR-214 in cervical cancer and promotes the growth and invasion of
HeLa cells. Int J Biochem Cell Biol. 43:632–641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang XJ, Ye H, Zeng CW, He B, Zhang H and
Chen YQ: Dysregulation of miR-15a and miR-214 in human pancreatic
cancer. J Hematol Oncol. 3:462010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Duan Q, Wang X, Gong W, Ni L, Chen C, He
X, Chen F, Yang L, Wang P and Wang DW: ER stress negatively
modulates the expression of the miR-199a/214 cluster to regulates
tumor survival and progression in human hepatocellular cancer. PLoS
One. 7:e315182012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC,
Huang CH, Lee YS, Yen TC and Hsieh SY: MicroRNA-214 downregulation
contributes to tumor angiogenesis by inducing secretion of the
hepatoma-derived growth factor in human hepatoma. J Hepatol.
57:584–591. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Uesugi A, Kozaki K, Tsuruta T, Furuta M,
Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive
microRNA miR-218 targets the mTOR component Rictor and inhibits AKT
phosphorylation in oral cancer. Cancer Res. 71:5765–5778. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alajez NM, Lenarduzzi M, Ito E, Hui AB,
Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, et al: MiR-218
suppresses nasopharyngeal cancer progression through downregulation
of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71:2381–2391.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tatarano S, Chiyomaru T, Kawakami K,
Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama
K, Seki N, et al: miR-218 on the genomic loss region of chromosome
4p15.31 functions as a tumor suppressor in bladder cancer. Int J
Oncol. 39:13–21. 2011.PubMed/NCBI
|
|
34
|
Cheng Y, Yang X, Deng X, Zhang X, Li P,
Tao J and Lu Q: MicroRNA-218 inhibits bladder cancer cell
proliferation, migration, and invasion by targeting BMI-1. Tumour
Biol. 36:8015–8023. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang J, Zhang X, Wang L, Yang Y, Dong Z,
Wang H, Du L and Wang C: MicroRNA-214 suppresses oncogenesis and
exerts impact on prognosis by targeting PDRG1 in bladder cancer.
PLoS One. 10:e01180862015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang LL, Guo YJ, Zhao CN and Gao JY:
Effects and mechanism of miR-214 on hepatocellular carcinoma. Asian
Pac J Trop Med. 8:392–398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z
and Jiang J: MiR-214 inhibits cell growth in hepatocellular
carcinoma through suppression of β-catenin. Biochem Biophys Res
Commun. 428:525–531. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yamane K, Jinnin M, Etoh T, Kobayashi Y,
Shimozono N, Fukushima S, Masuguchi S, Maruo K, Inoue Y, Ishihara
T, et al: Down-regulation of miR-124/-214 in cutaneous squamous
cell carcinoma mediates abnormal cell proliferation via the
induction of ERK. J Mol Med Berl. 91:69–81. 2013. View Article : Google Scholar
|
|
39
|
Wen Z, Lei Z, Jin-An M, Xue-Zhen L,
Xing-Nan Z and Xiu-Wen D: The inhibitory role of miR-214 in
cervical cancer cells through directly targeting mitochondrial
transcription factor A (TFAM). Eur J Gynaecol Oncol. 35:676–682.
2014.
|
|
40
|
Long LM, He BF, Huang GQ, Guo YH, Liu YS
and Huo JR: microRNA-214 functions as a tumor suppressor in human
colon cancer via the suppression of ADP-ribosylation factor-like
protein 2. Oncol Lett. 9:645–650. 2015.PubMed/NCBI
|
|
41
|
Song L, Li D, Zhao Y, Gu Y, Zhao D, Li X,
Bai X, Sun Y, Zhang X, Sun H, et al: miR-218 suppressed the growth
of lung carcinoma by reducing MEF2D expression. Tumour Biol. Sep
26–2015.Epub ahead of print.
|
|
42
|
Cao Q, Dong P and Wang Y, Zhang J, Shi X
and Wang Y: miR-218 suppresses cardiac myxoma proliferation by
targeting myocyte enhancer factor 2D. Oncol Rep. 33:2606–2612.
2015.PubMed/NCBI
|
|
43
|
Jun GJ, Zhong GG and Ming ZS: miR-218
inhibits the proliferation of glioma U87 cells through the
inactivation of the CDK6/cyclin D1/p21Cip1/Waf1 pathway.
Oncol Lett. 9:2743–2749. 2015.PubMed/NCBI
|
|
44
|
Wang T, Chen T, Niu H, Li C, Xu C, Li Y,
Huang R, Zhao J and Wu S: MicroRNA-218 inhibits the proliferation
and metastasis of esophageal squamous cell carcinoma cells by
targeting BMI1. Int J Mol Med. 36:93–102. 2015.PubMed/NCBI
|
|
45
|
Heishima K, Mori T, Sakai H, Sugito N,
Murakami M, Yamada N, Akao Y and Maruo K: MicroRNA-214 promotes
apoptosis in canine hemangiosarcoma by targeting the COP1-p53 axis.
PLoS One. 10:e01373612015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Phatak P, Byrnes KA, Mansour D, Liu L, Cao
S, Li R, Rao JN, Turner DJ, Wang JY and Donahue JM: Overexpression
of miR-214-3p in esophageal squamous cancer cells enhances
sensitivity to cisplatin by targeting survivin directly and
indirectly through CUG-BP1. Oncogene. View Article : Google Scholar : Epub ahead of
print.
|
|
47
|
Li PL, Zhang X, Wang LL, Du LT, Yang YM,
Li J and Wang CX: MicroRNA-218 is a prognostic indicator in
colorectal cancer and enhances 5-fluorouracil-induced apoptosis by
targeting BIRC5. Carcinogenesis. 36:1484–1493. 2015.PubMed/NCBI
|
|
48
|
He X, Xiao X, Dong L, Wan N, Zhou Z, Deng
H and Zhang X: MiR-218 regulates cisplatin chemosensitivity in
breast cancer by targeting BRCA1. Tumour Biol. 36:2065–2075. 2015.
View Article : Google Scholar
|
|
49
|
Xia H, Yan Y, Hu M, Wang Y, Wang Y, Dai Y,
Chen J, Di G, Chen X and Jiang X: MiR-218 sensitizes glioma cells
to apoptosis and inhibits tumorigenicity by regulating
ECOP-mediated suppression of NF-κB activity. Neuro Oncol.
15:413–422. 2013. View Article : Google Scholar :
|
|
50
|
Jin Y, Yang CJ, Xu X, Cao JN, Feng QT and
Yang J: MiR-214 regulates the pathogenesis of patients with
coronary artery disease by targeting VEGF. Mol Cell Biochem.
402:111–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang TS, Yang XH, Wang XD, Wang YL, Zhou B
and Song ZS: MiR-214 regulate gastric cancer cell proliferation,
migration and invasion by targeting PTEN. Cancer Cell Int.
13:682013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu Z, Xu Y, Long J, Guo K, Ge C and Du R:
microRNA-218 suppresses the proliferation, invasion and promotes
apoptosis of pancreatic cancer cells by targeting HMGB1. Chin J
Cancer Res. 27:247–257. 2015.PubMed/NCBI
|
|
53
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jin J, Cai L, Liu ZM and Zhou XS:
miRNA-218 inhibits osteosarcoma cell migration and invasion by
down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev.
14:3681–3684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lee TS, Lin JJ, Huo YN and Lee WS:
Progesterone inhibits endothelial cell migration through
suppression of the rho activity mediated by cSrc activation. J Cell
Biochem. 116:1411–1418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
van der Horst PH, Wang Y, Vandenput I,
Kühne LC, Ewing PC, van Ijcken WF, van der Zee M, Amant F, Burger
CW and Blok LJ: Progesterone inhibits epithelial-to-mesenchymal
transition in endometrial cancer. PLoS One. 7:e308402012.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bokhari AA, Lee LR, Raboteau D, Hamilton
CA, Maxwell GL, Rodriguez GC and Syed V: Progesterone inhibits
endometrial cancer invasiveness by inhibiting the TGFβ pathway.
Cancer Prev Res (Phila). 7:1045–1055. 2014. View Article : Google Scholar
|
|
58
|
Xie M, Zhou L, Chen X, Gainey LO, Xiao J,
Nanes MS, Hou A, You S and Chen Q: Progesterone and Src family
inhibitor PP1 synergistically inhibit cell migration and invasion
of human basal phenotype breast cancer cells. BioMed Res Int.
2015:4264292015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A,
Fazli L, Cox M, Plymate S, Gleave M and Dong X: Prostate stromal
cells express the progesterone receptor to control cancer cell
mobility. PLoS One. 9:e927142014. View Article : Google Scholar : PubMed/NCBI
|
